Janssen Biotech gets prostate cancer IP from Aduro BioTech; deal terminated
Executive Summary
Aduro BioTech Inc. (cancer immunotherapies) licensed Johnson & Johnson’s Janssen Biotech Inc. exclusive worldwide rights to prostate cancer candidates including preclinical ADU741, which are based on Aduro’s live-attenuated double-deleted (LADD) Listeria monocytogene platform.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice